Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COVETRUS, INC.CVET · Entity 123087 | See Remarks | July 01, 2020 | July 06, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Legal Officer, Secretary | May 02, 2022 | May 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COVETRUS, INC.
Report date July 01, 2020 · Filed July 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.38 · Expires 2028-04-12 | Direct | 96,805 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Disposition to issuer · Disposed 1,387 · Balance 96,805 F1: On February 7, 2019 (the "Closing Date"), in connection with the Agreement and Plan of Merger (the "Merger Agreement") by and among Henry Schein, Inc., HS Spinco, Inc., HS Merger Sub, Inc., Direct Vet Marketing, Inc., and Shareholder Representative Services, LLC, an aggregate total of 1,956,817 shares of common stock of Covetrus, Inc. and 154,354 options to acquire common stock of Covetrus were placed in escrow to satisfy certain potential purchase price adjustments under the Merger Agreement. In conjunction with the final settlement and release of the escrow, an aggregate total of 756,387 of such shares and options were cancelled, pro rata, including 1,387 options to acquire common stock held by the Reporting Person. F3: Not applicable. F2: The stock options were granted on April 12, 2018. The stock options vest and become exercisable as to 25% of the total shares on April 12, 2019 and thereafter, vest and become exercisable in 36 successive, equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 7, 2019 (the "Closing Date"), in connection with the Agreement and Plan of Merger (the "Merger Agreement") by and among Henry Schein, Inc., HS Spinco, Inc., HS Merger Sub, Inc., Direct Vet Marketing, Inc., and Shareholder Representative Services, LLC, an aggregate total of 1,956,817 shares of common stock of Covetrus, Inc. and 154,354 options to acquire common stock of Covetrus were placed in escrow to satisfy certain potential purchase price adjustments under the Merger Agreement. In conjunction with the final settlement and release of the escrow, an aggregate total of 756,387 of such shares and options were cancelled, pro rata, including 1,387 options to acquire common stock held by the Reporting Person.
F2: The stock options were granted on April 12, 2018. The stock options vest and become exercisable as to 25% of the total shares on April 12, 2019 and thereafter, vest and become exercisable in 36 successive, equal monthly installments.
F3: Not applicable.
Solid Biosciences Inc.
Report date May 02, 2022 · Filed May 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2032-05-02 | Direct | 254,000 |
Reported balance
After 2022-05-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-02 · Grant · Acquired 254,000 · Balance 254,000 F1: This option was granted on May 2, 2022 and vests in three equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 2, 2022 and vests in three equal annual installments beginning on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2022 Filed May 4, 2022 20:35 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 254,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001209191-22-027108 · doc4.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,000 Underlying: Common Stock · 254,000 shares Expires 2032-05-02 F1 · derivative.exercise_date: This option was granted on May 2, 2022 and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 81,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005683 · doc4.xml · derivative · entry 3 Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F4 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. F4 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005683 · doc4.xml · derivative · entry 2 Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 127,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-005683 · doc4.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 127,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| January 27, 2022 Filed Feb 1, 2022 21:45 UTC Amendment | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 81,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005932 · doc4a.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F2 · derivative.exercise_date: This amendment to the Form 4 filed on January 31, 2022 (the "Original Form 4") is being filed to correct the vesting information on a transaction reported on the Original Form 4. The restricted stock units were granted on January 27, 2022 and vest on the second anniversary of the grant date. F2 · derivative.expiration_date: This amendment to the Form 4 filed on January 31, 2022 (the "Original Form 4") is being filed to correct the vesting information on a transaction reported on the Original Form 4. The restricted stock units were granted on January 27, 2022 and vest on the second anniversary of the grant date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-21-016849 · doc4.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2031-03-01 F1 · derivative.exercise_date: This option was granted on March 1, 2021 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:43 UTC | COVETRUS, INC. CVET · Entity 123087 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,387 | Not disclosed Strike: $14.38 | Not disclosed |
DisclosureSEC source: 0001752836-20-000156 · wf-form4_159407537321111.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,805 Underlying: Common Stock · 1,387 shares Expires 2028-04-12 F1 · shares: On February 7, 2019 (the "Closing Date"), in connection with the Agreement and Plan of Merger (the "Merger Agreement") by and among Henry Schein, Inc., HS Spinco, Inc., HS Merger Sub, Inc., Direct Vet Marketing, Inc., and Shareholder Representative Services, LLC, an aggregate total of 1,956,817 shares of common stock of Covetrus, Inc. and 154,354 options to acquire common stock of Covetrus were placed in escrow to satisfy certain potential purchase price adjustments under the Merger Agreement. In conjunction with the final settlement and release of the escrow, an aggregate total of 756,387 of such shares and options were cancelled, pro rata, including 1,387 options to acquire common stock held by the Reporting Person. F3 · price: Not applicable. F2 · derivative.exercise_date: The stock options were granted on April 12, 2018. The stock options vest and become exercisable as to 25% of the total shares on April 12, 2019 and thereafter, vest and become exercisable in 36 successive, equal monthly installments. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:48 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 38,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000064 · wf-form4_158335847428790.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,990 Underlying: Common Stock · 38,990 shares Expires 2023-03-02 F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in three equal annual installments beginning on March 2, 2021. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:45 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000044 · wf-form4_158318912471371.xml · derivative · entry 3 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,336 Underlying: Common Stock · 1,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F3 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in three equal annual installments beginning on February 27, 2020. F3 · derivative.expiration_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in three equal annual installments beginning on February 27, 2020. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:45 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 579 | $10.71 | $6,201.09 |
DisclosureSEC source: 0001752836-20-000044 · wf-form4_158318912471371.xml · nonDerivative · entry 2 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,786 F1 · balance_after: Includes 1,013 shares acquired under the Covetrus Employee Stock Purchase Plan on November 30, 2019. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:45 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000044 · wf-form4_158318912471371.xml · nonDerivative · entry 1 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2019 Filed Aug 21, 2019 18:29 UTC | COVETRUS, INC. CVET · Entity 123087 | PurchaseCommon Stock | 1,684 | $14.90 | $25,091.60 |
DisclosureSEC source: 0001752836-19-000039 · wf-form4_156642655065906.xml · nonDerivative · entry 1 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684 Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,765 | $0.00 Strike: $37.47 | $0.00 |
DisclosureSEC source: 0000899243-19-005443 · doc4.xml · derivative · entry 2 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,765 Underlying: Common Stock · 14,765 shares Expires 2029-02-27 F3 · derivative.exercise_date: The stock options were granted on February 27, 2019. The stock options vest and become exercisable in three equal annual installments beginning on February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:21 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 5,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005443 · doc4.xml · derivative · entry 1 Brennan Erin Powers · CIK 0001764644 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,004 Underlying: Common Stock · 5,004 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in three equal annual installments beginning on February 27, 2020. F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in three equal annual installments beginning on February 27, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.